YD Bio Limited Ordinary Shares
YDES
Get informed when a big investor buys or sells
+ FollowMarket Cap$173.54M
Close$
$-0.13
106.2% downside
Current Fair Value
106.2% downsideOvervalued by 106.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $173.54 Million |
|---|---|
| Enterprise Value | $167.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | -0.13 |
| Outstanding Shares | 3,409,483 |
Return
| Return on Equity | 104.17% |
|---|---|
| Return on Assets | -21.59% |
| Return on Invested Capital | -24.61% |
Valuation & Multiples
| P/E Ratio | -1.5 |
|---|---|
| PEG | 1.33 |
| Price to Sales | - |
| Price to Book Ratio | -2.04 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -56.11 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▲ 0.03% |
|---|---|
| Total Invested | $1.23M▼ 28.83% |
| Investors Holding | 8▼ 2.00% |
ESG Score
No data
About YD Bio Limited Ordinary Shares
4 employees
CEO: Ethan Shen Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of ...